Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 75

1.

Management of plaque in people experiencing homelessness using 'peer education': a pilot study.

Paisi M, Witton R, Burrows M, Allen Z, Plessas A, Withers L, McDonald L, Kay E.

Br Dent J. 2019 Jun;226(11):860-866. doi: 10.1038/s41415-019-0361-0.

PMID:
31203339
2.

Fluorogenic atom transfer radical polymerization in aqueous media as a strategy for detection.

Allen ZT, Sackey-Addo JR, Hopps MP, Tahseen D, Anderson JT, Graf TA, Cooley CB.

Chem Sci. 2018 Nov 8;10(4):1017-1022. doi: 10.1039/c8sc03938k. eCollection 2019 Jan 28.

3.

Testing Trait-State Isomorphism in a New Domain: An Exploratory Manipulation of Openness to Experience.

van Allen ZM, Zelenski JM.

Front Psychol. 2018 Oct 15;9:1964. doi: 10.3389/fpsyg.2018.01964. eCollection 2018.

4.

The Temporal Dynamics of Arc Expression Regulate Cognitive Flexibility.

Wall MJ, Collins DR, Chery SL, Allen ZD, Pastuzyn ED, George AJ, Nikolova VD, Moy SS, Philpot BD, Shepherd JD, Müller J, Ehlers MD, Mabb AM, Corrêa SAL.

Neuron. 2018 Jun 27;98(6):1124-1132.e7. doi: 10.1016/j.neuron.2018.05.012. Epub 2018 May 31.

5.

TSPmap, a tool making use of traveling salesperson problem solvers in the efficient and accurate construction of high-density genetic linkage maps.

Monroe JG, Allen ZA, Tanger P, Mullen JL, Lovell JT, Moyers BT, Whitley D, McKay JK.

BioData Min. 2017 Dec 19;10:38. doi: 10.1186/s13040-017-0158-0. eCollection 2017.

6.

Sortilin-Related Receptor Expression in Human Neural Stem Cells Derived from Alzheimer's Disease Patients Carrying the APOE Epsilon 4 Allele.

Zollo A, Allen Z, Rasmussen HF, Iannuzzi F, Shi Y, Larsen A, Maier TJ, Matrone C.

Neural Plast. 2017;2017:1892612. doi: 10.1155/2017/1892612. Epub 2017 May 28.

7.

Determinants of theory of mind performance in Alzheimer's disease: A data-mining study.

Ramanan S, de Souza LC, Moreau N, Sarazin M, Teixeira AL, Allen Z, Guimarães HC, Caramelli P, Dubois B, Hornberger M, Bertoux M.

Cortex. 2017 Mar;88:8-18. doi: 10.1016/j.cortex.2016.11.014. Epub 2016 Nov 30.

PMID:
28012370
8.

Positive Affect and Cognitive Restoration: Investigating the Role of Valence and Arousal.

Nealis LJ, van Allen ZM, Zelenski JM.

PLoS One. 2016 Jan 19;11(1):e0147275. doi: 10.1371/journal.pone.0147275. eCollection 2016.

9.

Mitochondrial β-amyloid in Alzheimer's disease.

Borger E, Aitken L, Muirhead KE, Allen ZE, Ainge JA, Conway SJ, Gunn-Moore FJ.

Biochem Soc Trans. 2011 Aug;39(4):868-73. doi: 10.1042/BST0390868.

PMID:
21787315
10.

Erectile dysfunction is predictive of all-cause mortality in patients with prostate cancer treated with permanent interstitial brachytherapy.

Bittner N, Merrick GS, Galbreath RW, Butler WM, Lief JH, Allen ZA, Wallner KE.

BJU Int. 2012 Jan;109(2):220-5. doi: 10.1111/j.1464-410X.2011.10280.x. Epub 2011 Jul 6.

11.

Serum testosterone kinetics after brachytherapy for clinically localized prostate cancer.

Taira AV, Merrick GS, Galbreath RW, Butler WM, Lief JH, Allen ZA, Wallner KE.

Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):e33-8. doi: 10.1016/j.ijrobp.2011.01.027. Epub 2011 Apr 7.

PMID:
21477935
12.

The incidence of transition zone prostate cancer diagnosed by transperineal template-guided mapping biopsy: implications for treatment planning.

Patel V, Merrick GS, Allen ZA, Andreini H, Taubenslag W, Singh S, Butler WM, Adamovich E, Bittner N.

Urology. 2011 May;77(5):1148-52. doi: 10.1016/j.urology.2010.11.052. Epub 2011 Feb 18.

PMID:
21334045
13.

The effect of pro-qura case volume on post-implant prostate dosimetry.

Merrick GS, Lief JH, Grimm P, Sylvester J, Butler WM, Allen ZA.

Int J Radiat Oncol Biol Phys. 2011 Dec 1;81(5):e727-34. doi: 10.1016/j.ijrobp.2010.10.076. Epub 2011 Feb 6.

PMID:
21300452
14.

The correlation between annular treatment margins and biochemical failure in prostate brachytherapy patients with optimized intraprostatic dosimetry.

Bittner N, Merrick GS, Butler WM, Allen ZA, White B, Adamovich A, Wallner KE.

Brachytherapy. 2011 Sep-Oct;10(5):409-15. doi: 10.1016/j.brachy.2010.10.004. Epub 2010 Dec 28.

PMID:
21190902
15.
16.

Permanent prostate brachytherapy in prostate glands <20 cm(3).

Mayadev J, Merrick GS, Reed JR, Butler WM, Galbreath RW, Allen ZA, Wallner KE.

Int J Radiat Oncol Biol Phys. 2010 Apr;76(5):1450-5. doi: 10.1016/j.ijrobp.2009.04.014.

PMID:
20338476
17.

Postimplant rectal dosimetry is not dependent on 103Pd or 125I seed activity.

Merrick GS, Sylvester J, Grimm P, Allen ZA, Butler WM, Reed JL, Khanjian J.

Brachytherapy. 2011 Jan-Feb;10(1):35-43. doi: 10.1016/j.brachy.2009.12.001. Epub 2010 Feb 11.

PMID:
20153264
18.

cExternal beam radiation results in minimal changes in post void residual urine volumes during the treatment of clinically localized prostate cancer.

Orio PF 3rd, Merrick GS, Allen ZA, Butler WM, Wallner KE, Kurko BS, Galbreath RW.

Radiat Oncol. 2009 Jul 22;4:26. doi: 10.1186/1748-717X-4-26.

19.

Prebiopsy PSA velocity not reliable predictor of prostate cancer diagnosis, Gleason score, tumor location, or cancer volume after TTMB.

Bittner N, Merrick GS, Andreini H, Taubenslag W, Allen ZA, Butler WM, Anderson RL, Adamovich E, Wallner KE.

Urology. 2009 Jul;74(1):171-6. doi: 10.1016/j.urology.2008.12.013. Epub 2009 Feb 20.

PMID:
19232691
20.

Ascl1 is a required downstream effector of Gsx gene function in the embryonic mouse telencephalon.

Wang B, Waclaw RR, Allen ZJ 2nd, Guillemot F, Campbell K.

Neural Dev. 2009 Feb 10;4:5. doi: 10.1186/1749-8104-4-5.

21.

Pretreatment serum testosterone and androgen deprivation: effect on disease recurrence and overall survival in prostate cancer patients treated with brachytherapy.

Taira AV, Merrick GS, Galbreath RW, Butler WM, Wallner KE, Allen ZA, Lief JH, Adamovich E.

Int J Radiat Oncol Biol Phys. 2009 Jul 15;74(4):1143-9. doi: 10.1016/j.ijrobp.2008.09.046. Epub 2008 Dec 29.

PMID:
19117691
22.

Biochemical and functional outcomes following brachytherapy with or without supplemental therapies in men < or = 50 years of age with clinically organ-confined prostate cancer.

Merrick GS, Wallner KE, Galbreath RW, Butler WM, Brammer SG, Allen ZA, Lief JH, Adamovich E.

Am J Clin Oncol. 2008 Dec;31(6):539-44. doi: 10.1097/COC.0b013e318172dcb7.

PMID:
19060584
23.

Effects of the time interval between prostate brachytherapy and postimplant dosimetric evaluation in community practice: analysis of the Pro-Qura database.

Orio PF 3rd, Merrick GS, Grimm P, Blasko J, Sylvester J, Allen ZA, Butler WM, Chaudhry UU.

Am J Clin Oncol. 2008 Dec;31(6):523-31. doi: 10.1097/COC.0b013e31816fc95a.

PMID:
19060582
24.

Analysis of the Pro-Qura Database: rectal dose, implant quality, and brachytherapist's experience.

Loiselle CR, Waheed M, Sylvester J, Allen ZA, Grimm PD, Eulau S, Butler WM, Merrick GS.

Brachytherapy. 2009 Jan-Mar;8(1):34-9. doi: 10.1016/j.brachy.2008.09.003. Epub 2008 Dec 3.

PMID:
19056321
25.

Prostate cancer control and survival in Vietnam veterans exposed to Agent Orange.

Everly L, Merrick GS, Allen ZA, Butler WM, Wallner K, Lief JH, Galbreath RW, Adamovich E.

Brachytherapy. 2009 Jan-Mar;8(1):57-62. doi: 10.1016/j.brachy.2008.08.001. Epub 2008 Oct 26.

PMID:
18955017
26.

Influence of Pro-Qura-generated plans on postimplant dosimetric quality: a review of a multi-institutional database.

Allen Z, Merrick GS, Grimm P, Blasko J, Sylvester J, Butler W, Chaudry UU, Sitter M.

Med Dosim. 2008 Autumn;33(3):206-14. doi: 10.1016/j.meddos.2007.09.001. Epub 2008 Mar 17.

PMID:
18674685
27.

Primary causes of death after permanent prostate brachytherapy.

Bittner N, Merrick GS, Galbreath RW, Butler WM, Wallner KE, Allen ZA, Brammer SG, Moyad M.

Int J Radiat Oncol Biol Phys. 2008 Oct 1;72(2):433-40. doi: 10.1016/j.ijrobp.2008.02.013. Epub 2008 Apr 28.

PMID:
18448268
28.

Prostate brachytherapy in men > or =75 years of age.

Merrick GS, Wallner KE, Galbreath RW, Butler WM, Brammer SG, Allen ZA, Adamovich E.

Int J Radiat Oncol Biol Phys. 2008 Oct 1;72(2):415-20. doi: 10.1016/j.ijrobp.2008.01.017. Epub 2008 Apr 18.

PMID:
18374514
29.

Role of trospium chloride in brachytherapy-related detrusor overactivity.

Bittner N, Merrick GS, Brammer S, Niehaus A, Wallner KE, Butler WM, Allen ZA, Galbreath RW.

Urology. 2008 Mar;71(3):460-4. doi: 10.1016/j.urology.2007.10.023.

PMID:
18342187
30.

The morbidity of transperineal template-guided prostate mapping biopsy.

Merrick GS, Taubenslag W, Andreini H, Brammer S, Butler WM, Adamovich E, Allen Z, Anderson R, Wallner KE.

BJU Int. 2008 Jun;101(12):1524-9. doi: 10.1111/j.1464-410X.2008.07542.x. Epub 2008 Mar 5.

31.

Obesity is not predictive of overall survival following permanent prostate brachytherapy.

Merrick GS, Galbreath RW, Butler WM, Wallner KE, Allen ZA, Adamovich E.

Am J Clin Oncol. 2007 Dec;30(6):588-96.

PMID:
18091052
32.

Driving assessment and rehabilitation after stroke.

Allen ZA, Halbert J, Huang L.

Med J Aust. 2007 Nov 19;187(10):599. No abstract available.

PMID:
18021060
33.

Molecular identity of olfactory bulb interneurons: transcriptional codes of periglomerular neuron subtypes.

Allen ZJ 2nd, Waclaw RR, Colbert MC, Campbell K.

J Mol Histol. 2007 Dec;38(6):517-25. Epub 2007 Jul 12.

PMID:
17624499
34.

Dosimetry of an extracapsular anulus following permanent prostate brachytherapy.

Merrick GS, Butler WM, Wallner KE, Allen ZA, Kurko B, Anderson RL, Grammer R, Galbreath RW, True L, Adamovich E.

Am J Clin Oncol. 2007 Jun;30(3):228-33.

PMID:
17551297
35.

Primary Gleason pattern does not impact survival after permanent interstitial brachytherapy for Gleason score 7 prostate cancer.

Merrick GS, Galbreath RW, Butler WM, Waller KE, Allen ZA, Lief J, Adamovich E.

Cancer. 2007 Jul 15;110(2):289-96.

36.

Isotope and patient age predict for PSA spikes after permanent prostate brachytherapy.

Bostancic C, Merrick GS, Butler WM, Wallner KE, Allen Z, Galbreath R, Lief J, Gutman SE.

Int J Radiat Oncol Biol Phys. 2007 Aug 1;68(5):1431-7. Epub 2007 Jun 4.

PMID:
17544597
37.

Long-term rectal function after permanent prostate brachytherapy.

Merrick GS, Butler WM, Wallner KE, Galbreath RW, Allen ZA, Gutman S, Lief J.

Cancer J. 2007 Mar-Apr;13(2):95-104.

PMID:
17476137
38.

Prostate cancer distribution in patients diagnosed by transperineal template-guided saturation biopsy.

Merrick GS, Gutman S, Andreini H, Taubenslag W, Lindert DL, Curtis R, Adamovich E, Anderson R, Allen Z, Butler W, Wallner K.

Eur Urol. 2007 Sep;52(3):715-23. Epub 2007 Feb 23.

PMID:
17337114
39.

Androgen deprivation therapy does not impact cause-specific or overall survival in high-risk prostate cancer managed with brachytherapy and supplemental external beam.

Merrick GS, Butler WM, Wallner KE, Galbreath RW, Allen ZA, Adamovich E, Lief J.

Int J Radiat Oncol Biol Phys. 2007 May 1;68(1):34-40. Epub 2007 Feb 7.

PMID:
17289288
40.

Initial analysis of Pro-Qura: a multi-institutional database of prostate brachytherapy dosimetry.

Merrick GS, Grimm PD, Sylvester J, Blasko JC, Butler WM, Allen ZA, Chaudhry UU, Mazza A, Sitter M.

Brachytherapy. 2007 Jan-Mar;6(1):9-15.

PMID:
17284380
41.

Statins, especially atorvastatin, may improve survival following brachytherapy for clinically localized prostate cancer.

Moyad MA, Merrick GS, Butler WM, Wallner KE, Galbreath RW, Butler EG, Allen ZA, Adamovich E.

Urol Nurs. 2006 Aug;26(4):298-303.

PMID:
16939047
42.

Brachytherapy in men aged < or = 54 years with clinically localized prostate cancer.

Merrick GS, Wallner KE, Butler WM, Galbreath RW, Allen ZA, Adamovich E, True L.

BJU Int. 2006 Aug;98(2):324-8.

43.

Efficacy of neoadjuvant bicalutamide and dutasteride as a cytoreductive regimen before prostate brachytherapy.

Merrick GS, Butler WM, Wallner KE, Galbreath RW, Allen ZA, Kurko B.

Urology. 2006 Jul;68(1):116-20.

PMID:
16844453
44.

Temporal relationship between prostate brachytherapy and the diagnosis of colorectal cancer.

Gutman SA, Merrick GS, Butler WM, Wallner KE, Allen ZA, Galbreath RW, Adamovich E.

Int J Radiat Oncol Biol Phys. 2006 Sep 1;66(1):48-55. Epub 2006 Jun 5.

PMID:
16750312
45.

Androgen-deprivation therapy does not impact cause-specific or overall survival after permanent prostate brachytherapy.

Merrick GS, Butler WM, Wallner KE, Galbreath RW, Allen ZA, Adamovich E.

Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):669-77. Epub 2006 May 6.

PMID:
16682149
46.

Risk factors for the development of prostate brachytherapy related urethral strictures.

Merrick GS, Butler WM, Wallner KE, Galbreath RW, Anderson RL, Allen ZA, Adamovich E.

J Urol. 2006 Apr;175(4):1376-80; discussion 1381.

PMID:
16516001
47.

The zinc finger transcription factor Sp8 regulates the generation and diversity of olfactory bulb interneurons.

Waclaw RR, Allen ZJ 2nd, Bell SM, Erdélyi F, Szabó G, Potter SS, Campbell K.

Neuron. 2006 Feb 16;49(4):503-16.

48.

Selecting patients with pretreatment postvoid residual urine volume less than 100 mL may favorably influence brachytherapy-related urinary morbidity.

Beekman M, Merrick GS, Butler WM, Wallner KE, Allen ZA, Galbreath RW.

Urology. 2005 Dec;66(6):1266-70.

PMID:
16360455
49.

Variability of prostate brachytherapy pre-implant dosimetry: a multi-institutional analysis.

Merrick GS, Butler WM, Wallner KE, Blasko JC, Michalski J, Aronowitz J, Grimm P, Moran BJ, McLaughlin PW, Usher J, Lief JH, Allen ZA.

Brachytherapy. 2005;4(4):241-51.

PMID:
16344253
50.

Severity categories of the International Prostate Symptom Score before, and urinary morbidity after, permanent prostate brachytherapy.

Gutman S, Merrick GS, Butler WM, Wallner KE, Allen Z, Galbreath RW, Adamovich E.

BJU Int. 2006 Jan;97(1):62-8.

Supplemental Content

Support Center